

ARIC MANUSCRIPT PROPOSAL #865

February 7, 2002

PC Reviewed: 02/13/02

Status: D

Priority: _____

SC Reviewed: 02/14/02

Status: D

Priority: _____

1.a. Full Title

High Normal Blood Pressure and the Risk of Cardiovascular Disease

b. Abbreviated Title

High Normal BP & CVD

2. Writing Group

Lead: Abhi V. Kshirsagar

Address: Division of Nephrology & Hypertension
Campus Box #7155
Chapel Hill, NC 27599-7155

Phone: (919) 966-2561 Fax: (919)966-4251

E-mail: sagar@med.unc.edu

Members of Writing Group:

Myra Carpenter
Romulo E. Colindres
Heejung Bang
Sharon Wyatt

3. Time Line

Obtain data set:	March 2002
Begin statistical analysis:	March 2002
Complete statistical analysis:	June 2002
Complete manuscript:	October 2002

4. Rationale/Background

There is compelling evidence of a strong, continuous, positive association of systolic and diastolic blood pressure with cardiovascular disease (1-5).

As a matter of health (public) policy, U.S. and International organizations have categorized blood pressure into levels (6,7). The goals of this classification have been to identify those individuals at greatest risk for CVD and to set thresholds for initiation of therapy. Clinical practice patterns reflect this classification scheme. Therapy directed at lowering blood pressure in the general population occurs when the systolic blood pressure rises above 140 mm Hg and/or diastolic blood pressure rises above 90 mm Hg (8).

High normal blood pressure is defined as a SBP 130-139 mm Hg or a DBP 85-89 mm Hg (6). Individuals with high normal blood pressure are likely to have a higher risk of cardiovascular disease than individuals with normal (or optimal blood pressure) given the continuous relationship of blood pressure and CVD. There is a scant data quantifying the risk for individuals with high normal blood pressure.

Most recently, Vasani et al. (9) quantified the risk for CVD among individuals with high normal blood pressure from the Framingham Study (10). Having high normal blood pressure increased the risk of fatal & nonfatal CVD 2.5 fold among women and 1.6 fold among men compared to individuals with optimal levels of blood pressure. This increased risk held despite adjusting for most obvious covariates.

While the study by Vasani adds important information, it has some limitations that may be obviated by examining similar data from the ARIC cohort. Methodologically, the study was not able to adjust for insulin resistance, markers of systemic inflammation (fibrinogen, white blood cell count) (11,12), or for markers of endothelial dysfunction (von Willebrand Factor) (13). Because the investigators used a one-time blood pressure reading, the analysis was not able to adjust for regression dilution bias (1,14). Thus the true effect of high normal blood pressure may have been underestimated. Finally, the Framingham cohort included few minority participants.

5. Main Hypothesis

High normal blood pressure, as defined in the rationale, is associated with an elevated risk of fatal and nonfatal cardiovascular disease than individuals with normal or optimal blood pressure.

6. Data (variables, time window, source, inclusions/exclusions):

ARIC cohort visit 1 (and visit 2 for use in regression dilution analyses) blood pressure, age, race, gender, prevalence of hypertension, prevalence of CHD, medication use variables, insulin, glucose, cholesterol, LDL, HDL, triglycerides, von Willebrand Factor, fibrinogen, white blood cell count, BMI, diabetic status, smoking status, physical activity level, education level, incident CHD indicator, event date, and follow-up time.

Exclusions: hypertension, race other than black or white, prevalent CHD disease

Analysis summary: First of all, tests for the homogeneity of baseline characteristics among each comparison groups will be performed. The Kaplan-Meier estimates will be used to compute the cumulative incidence of CVD. Separate curves will be studied according to gender, race, and blood pressure category. In addition, the linearity of hazard over time will be also examined for each group. Multivariate Cox proportional hazards model will be constructed to evaluate the association between blood pressure and the risk of fatal and nonfatal CVD, adjusting other risk factors. Blood pressures available at two time points (visit 1 and visit 2) will be used to examine the effects of within-subject variability (regression dilution). In the model, the data measured over time will be incorporated as time-varying covariates and various potential effect modifications will also be tested. Hazard ratios of CVD for each group, compared to subjects with optimal level of blood pressure, will be calculated along with 95% confidence intervals.

All analyses will be done with SAS software (SAS Institute, Cary, N.C.). Two sided p-values will be used as criteria to assess statistical significance.

7.a. Will the data be used for non-CVD analysis in this manuscript?

Yes No

b. If Yes, is the author aware that the file ICTDER02 must be used to exclude persons with a value RES_OTH = "CVD Research" for non-DNA analysis, and for DNA analysis

RES_DNA = "CVD Research" would be used? Yes No

(This file ICTDER02 has been distributed to ARIC PIs, and contains

the responses to consent updates related to stored sample use for research.)

8.a. Will the DNA data be used in this manuscript? Yes No

8.b. If yes, is the author aware that either DNA data distributed by the Coordinating Center must be used, or the file ICTDER02 must be used to exclude those with value RES_DNA = "No use/storage DNA"? Yes No

9. The lead author of this manuscript proposal has reviewed the list of existing ARIC Study manuscript proposals and has found no overlap between this proposal and previously approved manuscript proposals either published or still in active status. ARIC Investigators have access to the publications lists under the Study Members Area of the web site at:

<http://bios.unc.edu/units/csc/ARIC/stdy/studymem.html>

Yes No

References

1. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. *Lancet* 1990;335:765-74.
2. Stamler J, Stamler N, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks: US population data. *Arch Intern Med* 1993; 153:598-615.
3. Stamler J, Dyer AR, Shekelle RB, Neaton JD, Stamler R. Relationship of baseline major risk factors to coronary and all cause mortality, and to longevity: findings from long-term follow-up of Chicago cohorts. *Cardiology* 1993;82:191-222.
4. van den Hoogen PCW, Feskens, EJM, Nagelkerke NJD, et al. The relationship between blood pressure and mortality due to coronary heart disease among men in different parts of the world. *N Engl J Med* 2000;342:1-8.
5. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. *JAMA* 1996;275:1571-6.
6. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *Arch Intern Med* 1997;157:2413-46.
7. Guideline Subcommittee. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. *J Hypertens* 1999;17:151-83.
8. Kaplan NM, Gifford RW. Choice of initial therapy for hypertension. *JAMA* 1996;20:1577-80.
9. Vasan RS, Larson, MG, Leip EP, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. *N Engl J Med* 2001;345:1291-7.
10. Dawber TR, Meadors GF, Moore FE Jr. Epidemiologic approaches to heart disease: the Framingham Study. *Am J Public Health* 1951;41:279-86.
11. Ernst E, Hammerschmidt DE, Bagge U, Martai A, Dormandy JA. Leukocytes and the risk of ischemic disease. *JAMA* 1987;25:2318-2324.
12. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. *N Engl J Med* 1997;336:973-9.
13. Farouque HMO, Meredith IT. The assessment of endothelial function in humans. *Coronary Artery Dis* 2001, 12:445-454.
14. Clarke R, Shipley M, Lewington S, et al. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. *Am J Epidemiol* 1999;150:341-53.